Acorda reports Q4 loss
-
- February
- 11
Acorda Therapeutics Inc., a biotechnology company in Hawthorne, reported this morning it lost $13.72 million during the fourth quarter of 2007, nearly double the $7 million loss a year earlier.
On a per-share basis, the company lost 48 cents in the quarter that ended in December, up from a loss of 30 cents during the last quarter of 2006.
But sales rose to $11.19 million, from $7.69 million.
Acorda markets Zanaflex, a treatment for involuntary muscle movements caused by multiple sclerosis and spinal injuries. It is trying to develop Fampridine-SR, another drug for treatment of multiple sclerosis.
Acorda shares closed Friday at $22.93, up 6 cents.
This entry was posted
on Monday, February 11th, 2008 at 9:16 am by Allan Drury.
You can follow any responses to this entry through the RSS 2.0 feed.
Print
| 
Email
